

toxin internalization, wherein said amino acid sequence induces an immune response against type F botulinum toxin when administered to an animal and said fusion protein further comprises an amino acid sequence which facilitates or enhances purification of said fusion protein.

~~Sub E3~~ 28. The fusion protein of claim 27 wherein said *C. botulinum* amino acid sequence consists of the contiguous amino acid sequence of amino acids 848 to 1278 of said *C. botulinum* neurotoxin.

~~29. The fusion protein of claim 28 wherein said *C. botulinum* amino acid sequence consists of SEQ ID NO: 1.~~

~~Sub E4~~ 30. The fusion protein of claim 27 wherein said *C. botulinum* neurotoxin amino acid sequence comprises at least one amino acid sequence selected from the contiguous amino acid sequence of amino acids 848-991 of said *C. botulinum* neurotoxin, the contiguous amino acid sequence of amino acids 992-1135 of said *C. botulinum* neurotoxin, or the contiguous amino acid sequence of amino acids 1136-1278 of said *C. botulinum* neurotoxin.

~~Sub G11~~ 31. A composition comprising the fusion protein of claim 27 and a diluent, said composition being free of contamination by other clostridial proteins.